Announcement

Collapse
No announcement yet.

BioAxone announces first patient treatment in acute spinal cord injury trial

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    BioAxone announces first patient treatment in acute spinal cord injury trial

    BioAxone announces first patient treatment in acute spinal cord injury trial
    MONTREAL, Feb. 7 /CNW Telbec/ - BioAxone Therapeutics Inc., a
    biopharmaceutical company, has announced the first patient administration of
    Cethrin(R) in the Phase I/IIa clinical trial for the treatment of acute spinal
    cord injury. The first patient was administered Cethrin by Dr. Nicholas
    Theodore, Neurosurgeon at St. Joseph's Hospital & Medical Center, Phoenix,
    Arizona.
    The Phase I/IIa clinical trial is a multinational study in which up to
    48 patients with acute spinal cord injury will be administered Cethrin(R). The
    study is designed to evaluate the safety and pharmacokinetics of rising doses
    of Cethrin(R), following a single extra-dural administration during surgery
    for acute thoracic and cervical spinal cord injury. The patients will be
    recruited from about 8 sites in Canada and the US.
    "This is a very important trial in the field of spinal cord injury. The
    novel therapeutic agent and the innovative delivery process represent
    significant milestones in our search to find better ways of treating patients
    with acute spinal cord injury", said Dr. Nicholas Theodore.
    "Cethrin(R) represents a unique approach for this treatment, and the
    procedure we have developed minimizes risk to patients because it is
    non-invasive", said Henry E. Khouri, PhD, MBA, Vice President, Clinical
    Development at BioAxone. "We are pleased to have enrolled
    http://www.newswire.ca/en/releases/a.../07/c1273.html



    http://stores.ebay.com/MAKSYM-Variety-Store
    http://stores.ebay.com/MAKSYM-Variety-Store
Working...
X